Helius Medical Technologies Inc. Class A (HSDT) is a prominent public health tech company renowned for its pioneering work in unique, non-invasive therapies. Its principal focus is discovering and developing revolutionary therapies for patients who suffer from diseases caused by neurological deficits. The company is committed to improving the quality of life for these individuals by harnessing the power of the nervous system to stimulate the brain's natural neuroplasticity healing capabilities.
The hallmark of Helius Medical Technologies is its pioneering PoNS™ device (Portable Neuromodulation Stimulator). This first-of-its-kind, non-invasive device has been clinically demonstrated to enhance the effectiveness of physical therapy. It is a wearable device that delivers gentle electrical stimulation to the surface of the tongue. This stimulation is believed to increase neural activity in the brain, potentially helping improve symptoms related to neurological disorders.
Helius Medical Technologies Inc. aims to carve a unique niche in the healthcare field with this innovative technology, catering to countless patients globally experiencing neurological symptoms. The company's determined focus on research, innovative thinking, commitment to patient care, and steadfast dedication to improving existing technology has resulted in a dynamic growth trajectory.
The company was established in 2014. Since its founding, it has consistently worked towards improving their technology and reaching new milestones in their field. With its headquarters based in Newtown, Pennsylvania, the company operates not just within the United States, but also globally, spreading its services across borders and expanding its reach worldwide. It is a public company whose shares are traded under the ticker symbol "HSDT" in NASDAQ.
Helius Medical Technologies Inc. strives to transform the healthcare landscape by creatively bridging technology and medicine. Its commitment to research and helping patients with neurological conditions using its novel PoNS™ device stands testimony to its mission. With constant advancements and continuous research, HSDT remains at the forefront of the health tech industry, revolutionizing treatment options and developing new ways to improve and manage the well-being of its patients. Through their entrepreneurial spirit and innovative approaches, Helius Medical Technologies Inc. underscores its role as a transformative force in medical technology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
HELIUS MEDICAL TECHNOLOGIES ($HSDT) announced its Q1 2026 earnings, reporting -$0.29 per share, beating analyst estimates of -$0.49. The company's revenue reached $3,620,000, surpassing the estimated $3,468,000. Hedge fund activity showed mixed sentiment, with some institutions increasing their positions and others decreasing them in recent quarters.
HELIUS MEDICAL TECHNOLOGIES (HSDT) announced its quarterly earnings results, reporting earnings of -$32.89 per share, significantly beating analyst estimates of -$51.51. The company also surpassed revenue expectations, bringing in $700,000 against an estimated $112,200. This report also highlights significant hedge fund activity, with several institutional investors increasing their stakes in HSDT during Q3 2025.
Helius Medical Technologies, Inc. has rebranded as Solana Company, signaling its commitment to the Solana blockchain. This move includes a strategic partnership with the Solana Foundation to exclusively conduct on-chain activities on Solana and potentially purchase SOL tokens at a discount. The company aims to maximize SOL per share and deliver on-chain yield for investors, leveraging Solana's fast processing speeds and native staking yield.
Helius Medical Technologies has acquired over 760,190 SOL tokens at an average cost of $231, initiating its $500 million digital asset treasury strategy. This move follows a 250% surge in HSDT shares earlier in the month after the announcement of the raise led by Pantera and Summer Capital. The company plans to scale its SOL position and explore staking and DeFi opportunities while retaining over $335 million in cash for future acquisitions.
Helius Medical Technologies (HSDT) has initiated its digital asset treasury strategy by acquiring over 760,190 SOL tokens at an average cost of $231, following a $500 million SOL treasury raise led by Pantera and Summer Capital. The company plans to scale its SOL position over 12-24 months, exploring staking and DeFi opportunities under a conservative risk framework. Despite a recent 14% drop in HSDT shares, the firm retains over $335 million in cash for further asset acquisition.